Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06936202 · ClinicalTrials.gov registry record · NA
Effects of Spirulina Supplementation on Mental Health in Healthy Adults
A NA study of Depression and Mental Acuity, sponsored by Arizona State University.
- Recruiting
- Registry status
- NA
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT06936202: Recruiting NA study of Depression and Mental Acuity, sponsored by Arizona State University.
NCT06936202 is a NA study of Depression and Mental Acuity that is actively recruiting participants, run by Arizona State University. The registered enrollment target is 30 participants, below the 786-participant average among 679 other Depression trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06936202, a NA study of Depression and Mental Acuity, is actively recruiting participants, sponsored by Arizona State University.
- RECRUITING
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
Spirulina platensis is a form of cyanobacteria, a blue-green algae, and is a superfood most known for being rich in protein, vitamins and minerals, and healthful phytochemicals. Spirulina supports brain health through neuroprotection offered by its antioxidants, anti-inflammatory properties, and hormone regulation. The aim of this study is to supplement healthy adults from a campus community with 3g of spirulina, daily, for 8 weeks to improve mood and mental acuity in comparison to receiving a placebo.
Primary Outcome
A validated measure consisting of 65 brief phrases, asking how they have personally felt over the last week, including today. The participants were asked to carefully rate their response on a 5-point Likert scale, ranging from 'not at all' to 'extremely'.
Conditions Studied
Interventions
- OTHER Placebo
- OTHER Spirulina capsules
Study Locations (1)
Arizona
- 850 PBC - Phoenix
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-04-15 |
| Est. Completion | 2026-05 |
| Phase | NA |
What NCT06936202 shows while recruiting
NCT06936202 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 786-participant average among 679 other Depression trials with a reported enrollment target (96% lower).
The record links to 2 conditions, with Depression appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06936202 reports a single indexed study location in Arizona.
Frequently Asked Questions
What is clinical trial NCT06936202 about?
NCT06936202 is a clinical study titled "Effects of Spirulina Supplementation on Mental Health in Healthy Adults". Spirulina platensis is a form of cyanobacteria, a blue-green algae, and is a superfood most known for being rich in protein, vitamins and minerals, and healthful phytochemicals. Spirulina supports brain health through neuroprotection offered by its antioxidants, anti-inflammatory properties, and hor...
What is the current status of trial NCT06936202?
This trial is currently recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2025-04-15. Estimated completion is 2026-05.
What conditions does trial NCT06936202 study?
This clinical trial studies the following conditions: Depression, Mental Acuity.
What interventions are being tested in trial NCT06936202?
The interventions under investigation include: Placebo (OTHER), Spirulina capsules (OTHER).
Who is sponsoring clinical trial NCT06936202?
This trial is sponsored by Arizona State University, which has 187 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06936202 being conducted?
This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Depression
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06936202's enrollment target sits among peer trials
30 557th of 679 higher than 105 of 679 other Depression trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Depression trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Reaching Out to Distressed Medical Residents, Fellows and Faculty
RECRUITING · NA
-
IMPACT (IMproving Proactive Approaches for Cancer Survivors' Mental Health Treatment)
RECRUITING · NA
-
Cold and Heat Investigation to Lower Levels of Depression
RECRUITING · NA
-
Dosing rTMS for Depression Post-SCI
RECRUITING · NA
-
Exploring Virtual Reality Adventure Training Exergaming
RECRUITING · NA
-
Brief Interventions for Coping with Distress
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy